is the new shingles vaccine proven to guard against alzheimer's

The short answer is no, not proven. The evidence is suggestive and biologically plausible, but it is not established, and the studies that exist are observational, which means they can show correlation, not causation.

The strongest recent evidence is a 2025 systematic review and meta-analysis that looked at the herpes zoster (shingles) vaccine and dementia risk. It found a protective association, but the authors themselves flagged substantial heterogeneity across the studies, meaning the studies were not measuring the same thing in the same way [1]. The pooled effect was a roughly 14% lower risk of dementia in vaccinated people, but when you have that much statistical noise, the real number could be meaningfully smaller or larger [1]. The same review also noted that the live-attenuated vaccine (Zostavax) and the newer adjuvanted recombinant vaccine (Shingrix) may have different effects, but the data on Shingrix specifically is much thinner because it has only been in wide use since 2017 [1].

There is also a 2025 systematic review and meta-analysis on the broader question of whether shingles infection itself raises dementia risk. It found a small increased risk after infection (about 14% higher), which supports the idea that preventing shingles might help the brain [2]. But again, the heterogeneity was extreme, and the authors could not rule out that people who get shingles are different from those who do not in ways that matter for dementia [2].

Here is the core problem: every study on this question is observational. People who get vaccinated are healthier, wealthier, and more health-conscious than people who do not. That is the "healthy user effect," and it can easily explain a 10-15% apparent benefit. The only way to prove this would be a randomized controlled trial, and the 2025 Delphi consensus on drug repurposing for Alzheimer's explicitly listed the shingles vaccine as a priority candidate specifically because it has not been tested in a randomized trial for this purpose [3]. The PROTECT platform trial they outline is designed to do exactly that, but it has not reported results yet [3].

The mechanism is plausible. Shingles is caused by reactivation of the varicella-zoster virus, which can travel to the brain and cause inflammation. The vaccine prevents that reactivation. But the vaccine also contains an adjuvant (AS01) that causes a strong inflammatory response of its own, and nobody has adequately studied whether that inflammation is neutral, beneficial, or harmful over decades [1]. The long-term safety data on Shingrix simply does not exist yet; the vaccine has only been on the market since 2017, and the pivotal trials followed people for about four years [1].

So here is the honest bottom line. If you are over 60 and deciding whether to get Shingrix to prevent shingles, the evidence for that is solid, and the pain of shingles is real. If you are getting it specifically to prevent Alzheimer's, you are acting on hope, not evidence. The association is real in the observational data, but it is exactly the kind of finding that has burned medicine before, like hormone replacement therapy looking great in observational studies and then failing in randomized trials. The PROTECT trial is the right way to answer this, and until it reports, the honest answer is that we do not know.

Confidence: High that the evidence is not yet sufficient to claim protection. Low to moderate that a true protective effect exists at all.